[1]刘晓哲,王 兵,刘俊超,等.药物涂层球囊在股腘动脉支架内再狭窄治疗中的应用 [J].介入放射学杂志,2018,27(05):410-414.
 LIU Xiaozhe,WANG Bing,LIU Junchao,et al.Application of drug- coated balloon in treating femoropopliteal in- stent restenosis[J].journal interventional radiology,2018,27(05):410-414.
点击复制

药物涂层球囊在股腘动脉支架内再狭窄治疗中的应用
()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
27
期数:
2018年05期
页码:
410-414
栏目:
血管介入
出版日期:
2018-05-25

文章信息/Info

Title:
Application of drug- coated balloon in treating femoropopliteal in- stent restenosis
作者:
刘晓哲 王 兵 刘俊超 丁 语 吴 斐 牛晓阳 孙利坤
Author(s):
LIU Xiaozhe WANG Bing LIU Junchao DING Yu WU Fei NIU Xiaoyang SUN Likun
Department of Vascular Surgery, the Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450052, China
关键词:
【关键词】 药物涂层球囊 股腘动脉 支架内再狭窄 通畅率
文献标志码:
A
摘要:
【摘要】 目的 评价药物涂层球囊(DCB)与普通球囊(CB)血管成形术治疗股腘动脉支架内再狭窄(ISR)的临床效果。方法 回顾性分析2016年1月至2017年1月收治的45例股腘动脉ISR患者临床资料,其中22例接受DCB治疗,23例接受CB治疗。术后 3、6、12个月随访两组患者靶血管最小管腔直径(MLD)、远期管腔丢失(LLL)、一期通畅率等指标并作对比分析。结果 45例患者手术均获成功,无截肢或死亡患者,无失防。DCB组与CB 组相比,靶血管一期通畅率在术后3个月差异无统计学意义(95.5%对86.9%,P>0.05),但术后6、12 个月明显升高(86.4%对69.6%,P<0.05;81.8%对47.8%,P<0.05)。两组术前、术后7 d、术后6个月靶血管MLD差异均无统计学意义(P>0.05),术后12个月DCB组明显高于CB组(P<0.05);术后12个月DCB组靶血管LLL明显低于CB组(P<0.05)。结论 DCB治疗股腘动脉ISR较CB优势明显,具有较好的近中期疗效。

参考文献/References:

[1] 李玉林, 文继航, 唐建武, 等. 病理学[M]. 第8版, 北京: 人民卫生出版社, 2013: 129- 130.
[2] Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery[J]. N Engl J Med, 2006, 354: 1879- 1888.
[3] Ng VG, Mena C, Pietras C, et al. Local delivery of paclitaxel in the treatment of peripheral arterial disease[J]. Eur J Clin Invest,2015, 45: 333- 345.
[4] Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo[J]. J Am Coll Cardiol, 2000, 29: 1969- 1976.
[5] Iida O, Soga Y, Hirano K, et al. Long- term outcomes and risk stratification of patency following nitinol stenting in the femoropliteal segment: retrospective multicenter analysis[J]. J Endovasc Ther, 2011, 18: 753- 761.
[6] Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve- month results from the RESILIENT randomized trial[J]. Circ Cardiovasc Interv, 2010, 3: 267- 276.
[7] Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting[J]. Circulation, 2007, 115:2745- 2749.
[8] Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery[J]. N Engl J Med, 2006, 354: 1879- 1888.
[9] Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12- month results of the DURABILITY I study[J]. J Endovasc Ther, 2009, 16: 261- 269.
[10] Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial(FAST)[J]. Circulation, 2007, 116:285- 292.
[11] Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropooliteal stenting[J]. J Am Coll Cardiol, 2012, 59: 16- 23.
[12] Yang X, Lu X, Li W, et al. Endovascular treatment for symptomatic stent failures in long- segment chronic total occlusion of femoropopliteal arteries[J]. J Vasc Surg, 2014, 60: 362- 368.
[13] Al Shammeri O, Bitar F, Ghitelman J, et al. Viabahn for femoropopliteal in- stent restenosis[J]. Ann Saudi Med, 2012,32: 572- 582.
[14] Bosiers M, Deloose K, Callaert J, et al. Superiority of stent- grafts for in- stent restenosis in the superficial femoral artery: twelve- month results from a multicenter randomized trial[J]. J Endovasc Ther, 2015, 22: 1- 10.
[15] Leopardi M, Houbballah R, Becquemin JP. Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis[J]. J Cardiovasc Surg(Torino), 2014, 55: 229- 234.
[16] Murata N, Takahara M, Soga Y, et al. Drug- eluting stent vs percutaneous transluminal angioplasty for treatment of femoropopliteal in- stent restenosis: results from a retrospective 1- year multicenter study[J]. J Endovasc Ther, 2016, 23: 642- 647.
[17] 李伟浩, 张 韬, 刘运峰. 经皮腔内斑块切除术治疗下肢动脉支架内再狭窄的荟萃分析[J]. 中华医学杂志, 2015, 95: 3625- 3630.
[18] Brodmann M, Rief P, Fruehlich H, et al. Neointimal hyperplasia after silverhawk atherectomy versus percutaneous transluminal angioplasty(PTA) in femoropopliteal stent reobs- truetions: a controlled, randomized pilot trial[J]. Cardiovasc Intervent Radiol, 2012, 36: 69- 74.
[19] 符伟国, 岳嘉宁. 股腘动脉段病变支架内再狭窄的腔内治疗策略分析[J]. 中华外科杂志, 2016, 54: 586- 590.
[20] 刘俊超, 王 兵. 药物涂层球囊治疗股腘动脉支架内再狭窄的研究进展[J]. 中国普通外科杂志, 2016, 25: 1796- 1800.
[21] Nishiyama N, Komatsu T, Kuroyanagi T, et al. Clinical value of drug- coated balloon angioplasty for de novo lesions in patients with coronary artery disease[J]. Int J Cardiol, 2016, 222: 113- 118.
[22] 郭 伟, 卫 任. 药物涂层球囊治疗周围动脉疾病的循证医学证据[J]. 中国普通外科杂志, 2016, 25: 785- 789.
[23] Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral- popliteal arteries with drug- coated balloons: 5- year follow- up of the THUNDER trial[J]. JACC Cardiovasc Interv, 2015, 8: 102- 108.
[24] Liistro F, Grotti S, Porto I, et al. Drug- eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE- SFA randomized trial[J]. JACC Cardiovasc Interv, 2013, 6: 1295- 1302.
[25] Alfonso F, Cuesta J. Long- term results of drug- coated balloons for drug- eluting in- stent restenosis: gaining perspective[J]. JACC Cardiovasc Interv, 2015, 8: 885- 888.
[26] Indermuehle A, Bahl R, Lansky AJ, et al. Drug- eluting balloon angioplasty for in- stent restenosis: a systematic review and meta- analysis of randomised controlled trial[J]. Heart, 2013, 99: 327- 233.
[27] Krankenberg H, Tübler T, Ingwersen M, et al. Drug- coated balloon versus standard balloon for superficial femoral artery in- stent restenosis. The randomized femoral artery in- stent restenosis(FAIR) trial[J]. Circulation, 2015, 132: 2230- 2236.
[28] Kinstner CM, Lammer J, Willfort- Ehringer A, et al. Paclitaxel- eluting balloon versus standard balloon angioplasty in in- stent restenosis of the superficial femoral and proximal popliteal artery: 1- year results of the PACUBA trial[J]. JACC Cardiovasc Interv, 2016, 9: 1386- 1392.
[29] Liistro F, Angioli P, Porto I, et al. Paclitaxel- eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in- stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE- ISR study[J]. J Endovasc Ther, 2014, 21: 1- 8.
[30] Grotti S, Liistro F, Angioli P, et al. Paclitaxel- eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in- stent restenosis of the super?覱cial femoral and proximal popliteal arteries: three- year results of the DEBATE- ISR study[J]. J Endovasc Ther, 2016, 23: 52- 57.
[31] 桑军侠. 紫杉醇脂质体联合顺铂治疗老年中晚期肺鳞癌的临床疗效及毒副作用研究[J]. 中国卫生标准管理, 2016, 7: 80- 81.
[32] 刘在亮, 蔡剑雄, 张 瑚. 紫杉醇脂质体注射液与普通紫杉醇治疗胃癌疗效与安全性的Meta分析[J]. 中国实验方剂学杂志, 2016, 22: 221- 225.
[33] Casadei GA, Tenti E, Masini C, et al. Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions[J]. Oncotarget, 2016, 7: 40719- 40724.

相似文献/References:

[1]钱钧,姜宏,杨晓红.内膜下再通术在股腘动脉腔内成形术中的应用[J].介入放射学杂志,2011,(02):103.
 QIAN Jun,JIANG Hong,YANG Xiao-hong..The application of subintimal recanalization in percutaneous transluminal angioplasty for chronic long-segment occlusion of femoropopliteal artery[J].journal interventional radiology,2011,(05):103.
[2]刘 蓉,马士新,赵 钢,等.紫杉醇药物涂层球囊扩张冠状动脉支架内再狭窄病变增加远期管腔面积 [J].介入放射学杂志,2017,(04):367.
 LIU Rong,MA Shixing,ZHAO Gang,et al.Long- term lumen area enlarged in coronary in- stent restenosis after the treatment of paclitaxel drug - coated balloon dilatation[J].journal interventional radiology,2017,(05):367.
[3]张成超,谷涌泉,齐立行,等.药物涂层球囊扩张成形术治疗颈动脉支架内再狭窄2例[J].介入放射学杂志,2019,28(02):159.
 ZHANG Chengchao,GU Yongquan,QI Lixing,et al.Drug- coated balloon dilatation for the treatment of carotid in- stent restenosis: initial results in 2 patients[J].journal interventional radiology,2019,28(05):159.
[4]陈 英.生化指标与股腘动脉慢性完全闭塞病变支架内再狭窄相关性分析[J].介入放射学杂志,2020,29(07):664.
 CHEN Ying..The correlation between biochemical indexes and in-stent restenosis of chronic total occlusion of femoropopliteal artery[J].journal interventional radiology,2020,29(05):664.
[5]胡学俊,马小林,刘 冰,等.药物涂层球囊治疗新生冠状动脉病变45例临床分析 [J].介入放射学杂志,2020,29(12):1258.
 HU Xuejun,MA Xiaoling,LIU Bing,et al.Drug-coated balloon for the treatment of de novo coronary lesions: clinical analysis of 45 patients[J].journal interventional radiology,2020,29(05):1258.
[6]潘 涛,田诗云,张 涛,等.贫血对股腘动脉硬化闭塞症患者药物涂层球囊治疗后再狭窄的影响[J].介入放射学杂志,2021,30(08):799.
 PAN Tao,TIAN Shiyun,ZHANG Tao,et al.The effect of anemia on restenosis in patients with femoropopliteal atherosclerotic occlusion after drug-coated balloon angioplasty[J].journal interventional radiology,2021,30(05):799.
[7]项以力,张温凯,杨 镛.药物涂层球囊和无涂层球囊治疗股腘动脉缺血性疾病疗效及安全性meta分析 [J].介入放射学杂志,2017,(06):500.
 XIANG Yili,ZHANG Wenkai,YANG Yong.Drug- coated balloon versus uncoated balloon angioplasty for femoropopliteal artery ischemic disease: a meta- analysis of curative effect and safety[J].journal interventional radiology,2017,(05):500.

备注/Memo

备注/Memo:
(收稿日期:2017-08-09)
(本文编辑:边 佶)
更新日期/Last Update: 2018-05-11